_1777294237270_124456903.png&w=64&q=75){kind=small}
Russia develops treatment for aggressive cancers
The Russian Ministry of Health announced the approval of the drug "Elivosa" for the treatment of advanced forms of breast and ovarian cancers. This medication relies on the active ingredient Vosuloparib, classified as a PARP inhibitor. It helps weaken and kill cancer cells by targeting DNA repair mechanisms. The treatment is primarily used for advanced epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, as well as HER2-negative breast cancer in patients who carry BRCA1/2 mutations. The goal of this medication is to prolong the period of disease stability and to provide a more targeted and effective treatment option for patients who have developed resistance to traditional therapies, particularly noting that platinum drug resistance has reached around 80% in cases, and approximately 70% of ovarian cancer patients experience relapse within three years of initial treatment.
Notice: This Is an AI-Generated Summary
Comments (0)